No products in the cart.
Rabbit Polyclonal Phospho-Cbl (Y700) antibody (STJ91036)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, IF, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000;
Recommended protocols: check protocols
Click or hover above images to see image description for Cbl (phospho Tyr700) Polyclonal Antibody.
Check alternative names for the antibodyExpand
CBL antibody, CBL2 antibody, RNF55 antibody,|4732447J05Rik antibody|C CBL antibody|Cas Br M (murine) ecotropic retroviral transforming sequence antibody|Casitas B lineage lymphoma proto oncogene antibody|Casitas B-lineage lymphoma proto-oncogene antibody|CBL 2 antibody|cbl antibody|CBL_HUMAN antibody|CBL2 antibody|E3 ubiquitin protein ligase CBL antibody|E3 ubiquitin-protein ligase CBL antibody|Oncogene CBL2 antibody|Proto oncogene c CBL antibody|Proto-oncogene c-CBL antibody|RGD1561386 antibody|RING finger protein 55 antibody|RNF55 antibody|Signal transduction protein CBL antibody|Phospho anti-CBL (Y774) antibody [E160] (ab32446)
SCBT cat No: sc-1651|sc-170|sc-393543|sc-398282|sc-8372|sc-390648|sc-390649|
Cbl (phospho Tyr700) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-Cbl (Y700) Polyclonal Antibody detects endogenous levels of Cbl protein only when phosphorylated at Y700.
Synthesized phospho-peptide derived from Cbl (phospho Tyr700) at AA range 640-720
WB, IHC, IF, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:10000;
|Molecular weight|| |
Cbl (phospho Tyr700) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Cbl (phospho Tyr700) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
E3 ubiquitin-protein ligase CBL antibody, Casitas B-lineage lymphoma proto-oncogene antibody, Proto-oncogene c-Cbl antibody, RING finger protein 55 antibody, Signal transduction protein CBL antibody
|Protein names|| |
E3 ubiquitin-protein ligase CBL , Casitas B-lineage lymphoma proto-oncogene , Proto-oncogene c-Cbl , RING finger protein 55 , Signal transduction protein CBL
|Protein function|| |
Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The ‘Tyr-731’ phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. /
|Involvement in disease|| |
Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (NSLL) [MIM:613563]: A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme. / The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain. / Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain. / Contains 1 RING-type zinc finger. / Contains 1 UBA domain.
|Protein post-translational modifications|| |
Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK. / Ubiquitinated, leading to its degradation via the proteasome.
|Protein cellular localization|| |
Cytoplasm / Cell membrane
AntibodyPlus can customize Cbl (phospho Tyr700) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: